Program with Abstracts
To view a particular conference abstract, please click on the abstract number.
Monday 24 October
| 8:00AM - 6:30PM | Conference Registration |
| 9:00AM - 9:15AM | Welcome Address |
| 9:15AM - 10:55AM | Session 1 - Cancer Immunology Chair: Jonathan Cebon |
| Louis Weiner: Monoclonal Antibody Immunotherapy abs#001 | |
| Mark Smyth: Tumor-induced immunosuppression - a novel target in CD73 abs#002 | |
| Michael Kershaw: Adoptive immunotherapy of AML and multiple myeloma using T cells gene-modified to respond against the Lewis-Y antigen abs#003 | |
| Weisan Chen: Vaccine induced tumor-specific effector and regulatory T cell responses in humans abs#004 | |
| 10:55AM - 11:30AM | Morning Tea |
| 11:30AM - 12:50PM | Session 2 - Antibody-based Therapies Chair: Louis Weiner |
| Andrew Scott: Novel approaches to Cancer Therapy with Recombinant Antibodies abs#005 | |
| Niall Tebbutt: Optimal selection of targeted therapies in advanced colorectal cancer: linking biomarker data with clinical trial outcomes abs#006 | |
| Terrance Johns: NON-AGONISTIC BIVALENT ANTIBODIES THAT PROMOTE C-MET DEGRADATION AND INHIBIT TUMOR GROWTH AND OTHERS SPECIFIC FOR TUMOR RELATED C-MET abs#007 | |
| John Seymour: Anti-CD20 Antibodies in Haematologic Malignancies: Where have we come from, where are we now, and where are we heading? abs#008 | |
| 12:50PM - 2:00PM | Lunch |
| 2:00PM - 3:40PM | Session 3 - Signalling Therapies Chair: Grant McArthur |
| Pasi Jänne, MD, PhD: Therapeutic Strategies for EGFR Inhibitor Resistant Cancers abs#009 | |
| Wayne Phillips: Pik3caH1047R mutation and Pten loss cooperate to initiate ovarian tumorigenesis in vivo abs#010 | |
| David Huang: Flipping on the apoptotic switch for cancer treatment abs#011 | |
| Neil Watkins: Hedgehog signaling: from flies to clinical trials abs#012 | |
| 3:40PM - 4:00PM | Afternoon Tea |
| 4:00PM - 5:20PM | Session 4 - Tumour Inflammation Chair: Bryan Williams |
| Danny Welch: Metastasis genetics, epigenetics and the tumor microenvironment abs#013 | |
| Matthias Ernst: Interleukin-11, a therapeutic target linking inflammation to gastrointestinal cancer abs#014 | |
| Mathew Vadas: Regulation of endothelial phenotypes abs#015 | |
| 5:30PM - 7:00PM | Welcome Cocktails |
Tuesday 25 October
| 8:30AM - 4:30PM | Registration Open |
| 9:00AM - 10:40AM | Session 5 - Tumour Angiogenesis Chair: Andrew Boyd |
| Ulf Eriksson: Role of VEGF-B in lipid and glucose metabolism – possible implications in tumor biology abs#016 | |
| Steven Stacker: Understanding the unique signalling pathways in lymphatic endothelium abs#017 | |
| Martin Lackmann: Targeting epha3 for the treatment of solid and hematopoietic tumours abs#018 | |
| Ruth Ganss: Remodeling of Tumour Vasculature: A new Approach to Therapy abs#019 | |
| 10:40AM - 11:15AM | Morning Tea |
| 11:15AM - 12:35PM | Session 6 - Epigenetic Therapy Chair: Andrew Wei |
| Susan Clark: Epigenetic changes in Cancer abs#020 | |
| Ricky Johnstone: Use of HDAC inhibitors alone and in combination for the treatment of cancer abs#021 | |
| John Mariadason: Mechanistic insight into apoptosis induction by histone deacetylase inhibitors (HDACi). abs#022 | |
| Glenn Marshall: Histone deacetylation as a treatment target in Myc-driven cancer abs#023 | |
| 12:35PM - 1:30PM | Lunch |
| 1:30PM - 3:10PM | Session 7 - Stem Cells and Apoptosis Chair: Doug Hilton |
| David Lane: Drugging the “Undruggable” new routes to cancer therapy. abs#024 | |
| Jane Visvader: The mammary epithelial hierarchy and its implications for understanding tumorigenesis abs#025 | |
| Mark Shackleton: Dynamic intra-tumoral evolution of human melanoma reveals limitations in applying concepts of normal stem cell biology to cancer abs#026 | |
| David Vaux: IAPs and Smac-mimetics abs#027 | |
| 3:10PM - 4:30PM | Afternoon Tea & Poster Session |
| Matthew Anaka: A subpopulation of slow cycling, invasive and therapy resistant melanoma cells identifies EMT-like processes in melanoma abs#101 | |
| Andreas Behren: EMT in melanoma is characterized by up-regulation of TSP-1 abs#103 | |
| Ingrid Burvenich: Optimizing pharmacokinetics and targeting properties of recombinant anti-Lewis Y antibody hu3S193 in A431 tumor-bearing mice abs#104 | |
| Glenn Cartwright: Synthesis and Biological Evaluation of Novel Fluoro-18 Labeled Positron Emission Tomography (PET) imaging agents for hypoxic tissues in tumours abs#105 | |
| Ming Chai: Beta-blocker therapy reduces breast cancer metastasis. abs#106 | |
| Anderly Chueh: Sustained IE gene induction is linked to HDACi-induced apoptosis in multiple tumour types abs#107 | |
| Nathalie Dhomen: Characterising a Braf-driven Murine Model of Melanoma abs#108 | |
| Judith Doherty: Development of appropriate in vitro and in vivo assays for the preclinical assessment of small molecule CSF-1R inhibitors. abs#109 | |
| Hendrik Falk: Screening for Inhibitors of MYST Family Acetyltransferases, a New Class of Epigenetic Drug Targets abs#110 | |
| Markus Germann: Stem-like cells as origin of prostate cancer progression to castration-resistance abs#111 | |
| Nadia Harun: Detection of EphA3+ Leukaemic Stem Cells in the Bone Marrow of Leukaemia Patients abs#112 | |
| Rebecca Johnston: High content screening for DNA damage response in normal breast epithelial cells abs#113 | |
| Caroline Le: Activation of the sympathetic nervous system dysregulates innate immune function in metastatic breast cancer. abs#114 | |
| Guillaume Lessene: Biological and Structural Characterization of BCL-XL Inhibitors abs#115 | |
| Zhanqi Liu: ADCC, CDC and binding activities of anti-Ley antibody hu3S193 with mutated Fc abs#116 | |
| Jordane Malaterre: Investigating the role of c-Myb proto-oncogene in intestinal stem cell function and tumorigenesis. abs#117 | |
| Alena Malyukova: hCDC4 regulates sensitivity to glucocorticoids in T-cell acute lymphoblastic leukaemia. abs#118 | |
| Anthony Natoli: The small molecule Focal Adhesion Kinase (FAK) inhibitor PF-562,271 inhibits tumour growth in an in vivo model of human triple-negative breast cancer and potentiates the effect of docetaxel therapy abs#119 | |
| Paul Neilsen: A targeted therapeutic approach for mutant p53-expressing tumours abs#120 | |
| Belinda Parker: Blocking tumour cell–specific Type I IFN signalling accelerates breast cancer metastasis in immunocompetent mouse models abs#121 | |
| Angelo Perani: Impact on product quality of high productive GS-CHO cell lines abs#122 | |
| Vinochani Pillay: Targeting mutant K-Ras with novel siRNA-antibody conjugates for the treatment of colorectal cancer abs#123 | |
| Fiona Simpson: EGFR endocytosis is dysregulated in human squamous cell carcinoma abs#124 | |
| Pavel Sluka: The Effect of Microenvironmental Factors on the Biology of Primary Prostate Cancer Cells in vitro abs#125 | |
| Bee Tan: FOXP3 overexpression inhibits growth of melanoma cells in vitro abs#126 | |
| April Tan: The receptor tyrosine kinase EphA3 is overexpressed on tumor vasculature and leukemic cells in bone-marrow biopsy samples from AML patients. abs#127 | |
| Narci Teoh: Cyclin E, p53 and miR-34a,b,c interactions that facilitate proliferative drive in murine and human hepatocarcinogenesis abs#128 | |
| Lars Tögel: The negative feedback regulator of MAPK/ERK signalling, DUSP5, is methylated in colon cancer abs#129 | |
| Mary Vail: An anti-EphA3 antibody, chIIIA4, targeting bone marrow-derived mesenchymal stromal attenuates tumour growth by disrupting the stromal and vascular architecture. abs#130 | |
| Ana Vargas: The Role of Type XI Collagen in Breast Cancer Progression abs#131 | |
| Kathryn Visser: Pharmacokinetic and pharmacodynamic (PK/PD) analysis of the small molecule Focal Adhesion Kinase (FAK) inhibitor PF-562,271 in an in vivo model of human triple negative breast cancer abs#132 | |
| Genevieve Whitty: Characterisation of Primary Prostate Cancer Cells in vitro abs#133 | |
| Glenn Powers: Engineered Diabodies for the Diagnosis and Therapy of Prostate and Ovarian Cancer abs#134 | |
| 6:30PM - 9:00PM | Speaker Dinner |
Wednesday 26 October
| 8:30AM - 1:30PM | Registration Open |
| 9:00AM - 10:40AM | Session 8 - Target Discovery and Validation Chair: Paul Waring |
| Florian Greten: Inflammation and tumor initiation abs#028 | |
| Roger Daly: Tyrosine kinase signalling networks in human cancer abs#029 | |
| Rob Ramsay: Targeting of the nuclear oncoprotein c-Myb by DNA vaccination abs#030 | |
| Andreas Strasser: The role of the Bcl-2 protein family in tumorigenesis and cancer therapy abs#031 | |
| 10:40AM - 11:15AM | Morning Tea |
| 11:15AM - 12:45PM | Session 9 - Cancer Genomics Chair: Joan Heath |
| Robyn Ward: Colorectal cancer – a model for genome, epigenome and environmental interactions abs#033 | |
| David Bowtell: Reclassifying ovarian cancer: Origins, subtypes and resistance to therapy. abs#034 | |
| Oliver Sieber: Genomic instability status in colorectal cancer and relationship to patient outcomes abs#035 | |
| 12:45PM - 1:00PM | Conclusion - Andrew Scott |